Clinical Trials
73 trialsCINC424A2X01B Rollover Protocol
Novartis
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Ono Pharmaceutical Co., Ltd.
IMG-7289-CTP-203
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
HU-F-AIM
Novartis
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
Eilean Therapeutics
MK-3543-017
Merck Sharp & Dohme LLC
GIV-IN-PV
Italfarmaco
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Disc Medicine, Inc
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Chengdu Zenitar Biomedical Technology Co., Ltd
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
Ionis Pharmaceuticals, Inc.
ROPE
iOMEDICO AG
SLN
Silence Therapeutics plc
Managed Access Programs for INC424, Ruxolitinib
Novartis
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
Novartis
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
PharmaEssentia Japan K.K.
Prospero
Novartis
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
PharmaEssentia
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Protagonist Therapeutics, Inc.
VERIFY
Protagonist Therapeutics, Inc.
THRIVE
Protagonist Therapeutics, Inc.
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
PharmaEssentia
PV
PharmaEssentia
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
BeBetter Med Inc
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Mabwell (Shanghai) Bioscience Co., Ltd.
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Italfarmaco
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
PharmaEssentia Japan K.K.
A Study to Evaluate P1101 in Japanese PV Patients
PharmaEssentia Japan K.K.
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Astex Pharmaceuticals, Inc.
PAVE
Novartis
PACIFIC
Protagonist Therapeutics, Inc.
Safety Evaluation Study for Patients With Polycythemia Vera
Perseus Proteomics Inc.
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Lynk Pharmaceuticals Co., Ltd
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Ascentage Pharma Group Inc.
Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.
Novartis
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
NS Pharma, Inc.
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Hoffmann-La Roche
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Hoffmann-La Roche
PAC326
CTI BioPharma
RESPONSE-2
Novartis
CONTI-PV
AOP Orphan Pharmaceuticals AG
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Incyte Corporation
Study of Select Combinations in Adults With Myelofibrosis
Novartis
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
Hamad Medical Corporation